Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) Stock Has Consensus Target Price of $17.33

Shares of Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX – Get Free Report) have earned a consensus rating of “Moderate Buy” from the five brokerages that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $17.33.

Several brokerages recently issued reports on QNRX. Wall Street Zen downgraded Quoin Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday. Canaccord Genuity Group began coverage on Quoin Pharmaceuticals in a report on Monday, October 19th. They issued a “buy” rating and a $18.00 price target on the stock. Lake Street Capital started coverage on Quoin Pharmaceuticals in a research note on Wednesday, September 23rd. They issued a “buy” rating and a $20.00 price target for the company. Weiss Ratings raised shares of Quoin Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. Finally, BTIG Research initiated coverage on shares of Quoin Pharmaceuticals in a report on Monday, October 12th. They set a “buy” rating and a $14.00 price objective for the company.

View Our Latest Report on QNRX

Insider Activity at Quoin Pharmaceuticals

In related news, CEO Michael Myers bought 20,490 shares of the company’s stock in a transaction that occurred on Monday, August 31st. The stock was purchased at an average price of $4.88 per share, for a total transaction of $99,991.20. Following the completion of the transaction, the chief executive officer owned 37,713 shares in the company, valued at $184,039.44. The trade was a 118.97% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Sally Lawlor bought 10,244 shares of the company’s stock in a transaction that occurred on Monday, August 31st. The shares were bought at an average price of $4.88 per share, with a total value of $49,990.72. Following the transaction, the chief financial officer owned 10,684 shares of the company’s stock, valued at $52,137.92. The trade was a 2,328.18% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 57,370 shares of company stock worth $279,966 over the last ninety days. 7.54% of the stock is owned by corporate insiders.

Institutional Trading of Quoin Pharmaceuticals

Several hedge funds have recently bought and sold shares of QNRX. Nantahala Capital Management LLC bought a new position in shares of Quoin Pharmaceuticals during the 3rd quarter valued at about $1,077,000. AIGH Capital Management LLC increased its holdings in shares of Quoin Pharmaceuticals by 237.5% in the third quarter. AIGH Capital Management LLC now owns 236,234 shares of the company’s stock worth $1,077,000 after purchasing an additional 166,234 shares during the last quarter. Finally, SummitTX Capital L.P. increased its holdings in shares of Quoin Pharmaceuticals by 54.8% in the first quarter. SummitTX Capital L.P. now owns 100,300 shares of the company’s stock worth $662,000 after purchasing an additional 35,505 shares during the last quarter. Hedge funds and other institutional investors own 8.63% of the company’s stock.

Quoin Pharmaceuticals Price Performance

NASDAQ:QNRX opened at $3.70 on Friday. The business’s 50-day simple moving average is $5.00 and its two-hundred day simple moving average is $5.78. The stock has a market cap of $17.76 million, a PE ratio of -0.19 and a beta of 1.71. Quoin Pharmaceuticals has a 52 week low of $3.25 and a 52 week high of $23.50.

Quoin Pharmaceuticals (NASDAQ:QNRX – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($1.52) by $0.55. Sell-side analysts anticipate that Quoin Pharmaceuticals will post -7.45 earnings per share for the current fiscal year.

About Quoin Pharmaceuticals

(Get Free Report)

Quoin Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing treatments for rare and orphan diseases, with an emphasis on conditions affecting the skin. Its lead investigational product, QRX003, is a topical therapy being developed for Netherton syndrome, a rare genetic skin disorder. The company has also described plans to explore the treatment’s potential in other skin conditions. QRX003 is investigational and has not been established as a proven treatment.

Further Reading

Analyst Recommendations for Quoin Pharmaceuticals (NASDAQ:QNRX)

Receive News & Ratings for Quoin Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quoin Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.